SAB Biotherapeutics
SABS
25 hedge funds and large institutions have $8.48M invested in SAB Biotherapeutics in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
14% more funds holding
Funds holding: 22 → 25 (+3)
0.16% more ownership
Funds ownership: 33.88% → 34.04% (+0.16%)
12% less capital invested
Capital invested by funds: $9.69M → $8.48M (-$1.21M)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HWM
HB Wealth Management
Atlanta,
Georgia
|
+$301K |
| 2 |
Kovitz Investment Group Partners
Chicago,
Illinois
|
+$53.2K |
| 3 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$33K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$28.5K |
| 5 |
BlackRock
New York
|
+$23.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$365K |
| 2 |
Millennium Management
New York
|
-$2.32K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$853 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$188 |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$19 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$19 | -6 | Closed |
|
SABS Hedge Fund Activity: Q3 2024 in Review
25 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q3 2024, worth a combined $8.48M — down 12% from $9.69M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new SABS positions and 2 closed out — a net gain of 4 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was HB Wealth Management, opening a new position worth an estimated $301K. The largest seller was RTW Investments, cutting an estimated $365K.
- 25 institutional investors held SAB Biotherapeutics (SABS) as of Q3 2024, up from 22 in Q2 2024.
- Funds reported $8.48M of SAB Biotherapeutics stock for Q3 2024, down 12% quarter-over-quarter.
- 6 funds opened new SAB Biotherapeutics positions in Q3 2024 and 2 closed out, a net change of +4 holders.
- The largest SAB Biotherapeutics buyer in Q3 2024 was HB Wealth Management, an estimated $301K added.
- The largest SAB Biotherapeutics seller in Q3 2024 was RTW Investments, an estimated $365K sold.
Based on aggregated 13F filings for Q3 2024.